Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


BRCA Testing

The internationally based experts discuss current BRCA genetic testing recommendations in Italy, France, and the United States
person default
Pierfranco Conte, MD
Véronique Diéras, MD
Mark E. Robson, MD
Released: November 24, 2020

This program is divided into several short segments which you can step through using the Video Chapters menu.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


Pierfranco Conte, MD

University of Padua
Padua, Italy
U.O.C. Oncology 2
Istituto Oncologico Veneto, IOV - IRCSS
Padova, Italy

Pierfranco Conte, MD, PhD, has discosed that he has received consulting fees from AstraZeneca, BristolMyersSquibb, Eli Lilly, Merck, and Roche, as well as fees for non-CME services from AstraZeneca, Merck, and Roche.
Véronique Diéras, MD

Head, Breast Group
Medical Oncology Department
Centre Eugene Marquis UNICANCER
Rennes, France

Véronique Diéras, MD, has disclosed that she has received consulting fees from Abbvie, AstraZeneca, MSD, and Pfizer.
Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Mark E. Robson, MD, has disclosed that he has received consulting fees from AstraZeneca and Pfizer.


Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists and other healthcare providers who care for patients with metastatic breast cancer around the world.


The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with metastatic breast cancer.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases

Ruth O'Regan, MD Lee Schwartzberg, MD, FACP Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Expert video from live CCO Webinar on using immune checkpoint inhibitors and antibody–drug conjugates for early-stage through metastatic TNBC

Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS Rita Nanda, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Commentary by Dr. Kevin Kalinsky: Sequencing checkpoint inhibitors and sacituzumab govitecan in advanced TNBC with vs without BRCA mutation, from CCO

Kevin Kalinsky, MD, MS Released: December 23, 2020

Downloadable slideset with key data from the 2020 SABCS Virtual Symposium from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: December 18, 2020

Video Chapters

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.